Kymera Therapeutics
KYMR
210 hedge funds and large institutions have $3.44B invested in Kymera Therapeutics in 2025 Q2 according to their latest regulatory filings, with 64 funds opening new positions, 69 increasing their positions, 52 reducing their positions, and 26 closing their positions.
219% more call options, than puts
Call options by funds: $10.1M | Put options by funds: $3.16M
146% more first-time investments, than exits
New positions opened: 64 | Existing positions closed: 26
72% more capital invested
Capital invested by funds: $2B → $3.44B (+$1.44B)
44% more funds holding in top 10
Funds holding in top 10: 9 → 13 (+4)
33% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 52
21% more funds holding
Funds holding: 173 → 210 (+37)
8.82% more ownership
Funds ownership: 112.19% → 121.01% (+8.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$35.2M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$30.9M |
| 3 |
CC
Commodore Capital
New York
|
+$25.8M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$22.6M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$17.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$25.9M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$21.5M |
| 3 |
Millennium Management
New York
|
-$15.6M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$11.8M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$8.09M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VCM
226
Versant Capital Management
Phoenix,
Arizona
| – | -$2.27K | -83 | Closed |
|
|
MAM
227
Meeder Asset Management
Dublin,
Ohio
| – | -$1.97K | -72 | Closed |
|
228
Amundi
Paris,
France
| – | -$948 | -40 | Closed |
|
|
C
229
Covestor
London,
United Kingdom
| – | -$999 | -29 | -88% |
|
|
CA
230
CoreCap Advisors
Southfield,
Michigan
| – | -$766 | -28 | Closed |
|
|
SC
231
Stephens Consulting
Flint,
Michigan
| – | -$411 | -15 | Closed |
|
|
HCP
232
Hexagon Capital Partners
Rogers,
Arkansas
| – | -$356 | -13 | Closed |
|
|
FDCDDQ
233
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| – | -$274 | -10 | Closed |
|
|
TWD
234
True Wealth Design
Akron,
Ohio
| – | -$165 | -6 | Closed |
|
|
GFPC
235
Global Financial Private Client
Sarasota,
Florida
| – | -$27 | -1 | Closed |
|
KYMR Hedge Fund Activity: Q2 2025 in Review
210 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Kymera Therapeutics (KYMR) for Q2 2025, worth a combined $3.44B — up 72% from $2B a quarter earlier.
Buyers outnumbered sellers: 64 funds opened new KYMR positions and 26 closed out — a net gain of 38 holders — while 69 added to existing stakes and 52 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $35.2M. The largest seller was Janus Henderson Group, cutting an estimated $25.9M.
- 210 institutional investors held Kymera Therapeutics (KYMR) as of Q2 2025, up from 173 in Q1 2025.
- Funds reported $3.44B of Kymera Therapeutics stock for Q2 2025, up 72% quarter-over-quarter.
- 64 funds opened new Kymera Therapeutics positions in Q2 2025 and 26 closed out, a net change of +38 holders.
- The largest Kymera Therapeutics buyer in Q2 2025 was Fidelity Investments, an estimated $35.2M added.
- The largest Kymera Therapeutics seller in Q2 2025 was Janus Henderson Group, an estimated $25.9M sold.
Based on aggregated 13F filings for Q2 2025.